ADMA Biologics Changes Auditors to BDO USA, LLP
Ticker: ADMA · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
Related Tickers: ADMA
TL;DR
ADMA swapped PwC for BDO as their auditor, no drama reported.
AI Summary
ADMA Biologics, Inc. filed an 8-K on October 31, 2024, to report a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged BDO USA, LLP as its new independent registered public accounting firm, effective October 31, 2024. This change is not related to any disagreements with PricewaterhouseCoopers.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, though in this case, no disagreements were cited.
Risk Assessment
Risk Level: low — The filing is a routine change of auditor without any stated disagreements, indicating low immediate risk.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — Former Certifying Accountant
- BDO USA, LLP (company) — New Certifying Accountant
- October 31, 2024 (date) — Effective Date of Change
FAQ
When was the change in ADMA Biologics' certifying accountant effective?
The change was effective as of October 31, 2024.
Who was ADMA Biologics' previous certifying accountant?
ADMA Biologics' previous certifying accountant was PricewaterhouseCoopers LLP.
Who is ADMA Biologics' new independent registered public accounting firm?
ADMA Biologics' new independent registered public accounting firm is BDO USA, LLP.
Were there any disagreements between ADMA Biologics and PricewaterhouseCoopers LLP?
No, the filing explicitly states that there were no disagreements or reportable events between ADMA Biologics and PricewaterhouseCoopers LLP.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in the registrant's certifying accountant.
Filing Stats: 621 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-10-31 17:25:48
Filing Documents
- ef20037117_8k.htm (8-K) — 31KB
- 0001140361-24-044808.txt ( ) — 162KB
- adma-20241031.xsd (EX-101.SCH) — 4KB
- adma-20241031_lab.xml (EX-101.LAB) — 21KB
- adma-20241031_pre.xml (EX-101.PRE) — 16KB
- ef20037117_8k_htm.xml (XML) — 4KB
01
Item 4.01. Changes in Registrant's Certifying Accountant. (b) Engagement of New Independent Registered Public Accounting Firm On October 31, 2024, ADMA Biologics, Inc. (the "Company") and KPMG LLP ("KPMG") executed an agreement pursuant to which KPMG will initiate its engagement and serve as the Company's new independent registered public accounting firm effective upon the filing of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. KPMG's engagement will include an audit of Company's consolidated financial statements for the fiscal year ending December 31, 2024, which will be filed as part of the Company's Annual Report on Form 10-K anticipated to be filed on or before March 3, 2025. During the fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through October 31, 2024, the Company did not consult with KPMG with respect to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the Company's financial statements, and no written report or oral advice was provided to the Company by KPMG that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was subject to any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADMA Biologics, Inc. October 31, 2024 By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer